Harrow Health, Inc. (HROW)
HROW Stock Price Chart
Explore Harrow Health, Inc. interactive price chart. Choose custom timeframes to analyze HROW price movements and trends.
HROW Company Profile
Discover essential business fundamentals and corporate details for Harrow Health, Inc. (HROW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
28 Sept 2007
Employees
382.00
Website
https://www.harrowinc.comCEO
Mark L. Baum
Description
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
HROW Financial Timeline
Browse a chronological timeline of Harrow Health, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.23, while revenue estimate is $70.62m.
Earnings released on 11 May 2026
EPS came in at -$0.74 falling short of the estimated -$0.43 by -72.09%, while revenue for the quarter reached $44.20m , missing expectations by -15.69%.
Earnings released on 2 Mar 2026
EPS came in at $0.26 falling short of the estimated $0.40 by -35.00%, while revenue for the quarter reached $89.09m , missing expectations by -1.00%.
Earnings released on 10 Nov 2025
EPS came in at $0.33 surpassing the estimated $0.22 by +50.00%, while revenue for the quarter reached $71.64m , missing expectations by -18.62%.
Earnings released on 11 Aug 2025
EPS came in at $0.24 falling short of the estimated $0.31 by -23.40%, while revenue for the quarter reached $63.74m , missing expectations by -13.80%.
Earnings released on 8 May 2025
EPS came in at -$0.38 falling short of the estimated $0.02 by -2.00k%, while revenue for the quarter reached $47.83m , missing expectations by -29.53%.
Earnings released on 27 Mar 2025
EPS came in at $0.25 surpassing the estimated $0.11 by +127.27%, while revenue for the quarter reached $66.83m , beating expectations by +14.42%.
Earnings released on 13 Nov 2024
EPS came in at -$0.12 falling short of the estimated -$0.05 by -140.00%, while revenue for the quarter reached $49.26m , missing expectations by -16.64%.
Earnings released on 7 Aug 2024
EPS came in at -$0.13 surpassing the estimated -$0.25 by +48.00%, while revenue for the quarter reached $48.94m , missing expectations by -0.25%.
Earnings released on 13 May 2024
EPS came in at -$0.28 falling short of the estimated -$0.25 by -12.00%, while revenue for the quarter reached $34.59m , missing expectations by -7.20%.
Earnings released on 19 Mar 2024
EPS came in at -$0.27 falling short of the estimated -$0.05 by -455.56%, while revenue for the quarter reached $36.36m , missing expectations by -3.98%.
Earnings released on 13 Nov 2023
EPS came in at -$0.09 falling short of the estimated -$0.02 by -467.82%, while revenue for the quarter reached $34.27m , missing expectations by -9.50%.
Earnings released on 9 Aug 2023
EPS came in at -$0.02 falling short of the estimated -$0.01 by -250.26%, while revenue for the quarter reached $33.47m , missing expectations by -11.94%.
Earnings released on 11 May 2023
EPS came in at -$0.03 surpassing the estimated -$0.06 by +50.00%, while revenue for the quarter reached $26.10m , beating expectations by +3.79%.
Earnings released on 23 Mar 2023
EPS came in at $0.07 surpassing the estimated -$0.15 by +146.67%, while revenue for the quarter reached $20.33m , missing expectations by -5.00%.
Earnings released on 14 Nov 2022
EPS came in at -$0.06 falling short of the estimated -$0.00 by -9.58k%, while revenue for the quarter reached $22.82m , missing expectations by -1.39%.
Earnings released on 9 Aug 2022
EPS came in at $0.01 surpassing the estimated -$0.00 by +3.33k%, while revenue for the quarter reached $23.32m , beating expectations by +5.66%.
Earnings released on 5 May 2022
EPS came in at $0.03 surpassing the estimated $0.01 by +185.71%, while revenue for the quarter reached $22.12m , beating expectations by +13.53%.
Earnings released on 10 Mar 2022
EPS came in at -$0.01 falling short of the estimated $0.08 by -112.50%, while revenue for the quarter reached $20.19m , beating expectations by +4.34%.
Earnings released on 9 Nov 2021
EPS came in at $0.05 surpassing the estimated -$0.00 by +1.14k%, while revenue for the quarter reached $18.71m , beating expectations by +21.21%.
Earnings released on 10 Aug 2021
EPS came in at -$0.11 surpassing the estimated -$0.13 by +15.38%, while revenue for the quarter reached $18.13m , beating expectations by +15.43%.
HROW Stock Performance
Access detailed HROW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
